This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Oct. 23, 2012 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of synthetic biologics and innovative medicines for serious diseases and unmet medical needs, announced today that
Andrew Bristol, Ph.D., joined the team as its new Vice President of Research & Development. Dr. Bristol has over 20 years of experience in cancer research and drug development with a special emphasis on monoclonal antibodies and cancer vaccines. The Company also announced that
Michael Kaleko, M.D., Ph.D., has been promoted to Senior Vice President of Research & Development.
Dr. Bristol comes to Synthetic Biologics after working with the National Institutes of Health (NIH) as a Post-doctoral Fellow, focusing on the development of cellular immunotherapy and anti-cancer vaccines. In 1998, he joined Genetic Therapy, Inc. (a Novartis company) and rose to the position of Senior Scientist & Deputy Program Head of the Immunology Program. In 2003, he co-founded Neogenix Oncology, a company focused on the discovery and product development using human cancer tissue extracts as starting material to generate anti-cancer monoclonal antibodies. He spent the next 10 years with Neogenix, leading the company to win numerous awards, including the 2010 Maryland Technology Council's "Emerging Company of the Year" award and the 2007 Frost & Sullivan "Excellence in Research" award. Prior to joining Synthetic Biologics, he was the Founder and General Manager of Bristol Consulting Services.
Dr. Bristol earned his Ph.D. degree from
Tufts University, and his B.A. degree in Molecular Biology from the
University of California, Berkeley.
Jeffrey Riley, Chief Executive Officer at Synthetic Biologics, stated, "We are pleased to welcome Andy to Synthetic Biologics and expect that his extensive knowledge and biotechnology experience – especially in the development of monoclonal antibodies and successfully navigating the drug development process – will be vital in moving our projects forward."
"Since Mike joined Synthetic Biologics he has been invaluable to us as we continue to expand our synthetic biologics and DNA-based human therapeutics research. He has been integral in ramping up both our synthetic DNA and monoclonal antibody programs with Intrexon," concluded Mr. Riley.